+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Wearable Injectors Market - Forecasts from 2022 to 2027

  • PDF Icon


  • 135 Pages
  • August 2022
  • Region: Global
  • Knowledge Sourcing Intelligence LLP
  • ID: 5649196
The global wearable injectors market is projected to witness a CAGR of 20.67% during the forecast period to reach a total market size of US$17.271 billion by 2027, increasing from US$4.636 billion in 2020. Wearable injectors are medical devices used for drug delivery systems. It is attached to the patient to deliver the drugs in a controlled manner. For the same reason, the devices are also called patch pumps or patch injectors. These devices are typically used for high-volume medications, drugs with high viscosities, and medicines that are required at regular intervals over a long period of time. The device reduces the need for multiple painful injections, making it convenient and user-friendly.

Market Drivers

The growing prevalence of chronic diseases and changing lifestyles around the globe are considered the key drivers for the growth of the global wearable injector market. Wearable injectors are easy to use, especially when regular intervals of medication are required, thus providing a significant advantage over manual injections. The wearable injectors are user-friendly, making them easy to self-administer. They also do not interfere with the user's day-to-day life. Wearable injector devices improve dose accuracy and prevent needlestick injuries. Furthermore, rising healthcare costs and changes in technology have come up with innovative solutions that are not just efficient for managing the disease but also reduce the number of trips to hospitals and clinics to receive medical support for an injection.

Growth Factors

There are an increasing number of chronic diseases and lifestyle changes.

Chronic or non-communicable diseases like cancer, hypertension, diabetes, cardiovascular diseases, etc. are the leading causes of death globally. According to the World Health Organisation (WHO), 71% of all deaths are due to non-communicable diseases (NCDs). Globally, 17.9 million people are diseased due to cardiovascular disease, annually. This is followed by cancer, respiratory diseases, and diabetes, accounting for 9.3 million, 4.1 million, and 1.5 million deaths, respectively. Wearable injectors play an important role in managing non-communicable diseases like cardiovascular disease, cancer, diabetes, and autoimmune disease, amongst other diseases. In particular, with the growing sedentary lifestyle. Wearable injectors are a highly used device to deliver drugs prescribed by the doctor at a regular interval. This eliminates the possibility of the drug being over-or under-dosed. Not only is it user-friendly, but it also saves time and money by reducing the number of trips to hospitals for medical assistance for injections.

Technology advancement and increasing awareness

With the increase in awareness of health, precautionary measures, and increased research and development in the medical industry, solutions like wearable injectors play an important role in assisting with various non-communicable diseases. As individuals are becoming more health-conscious, they are not just becoming aware of diseases but of all the alternative treatments and medical devices that are available for the management of such diseases. Several steps are taken by governments and international organizations to raise awareness amongst the citizens to ensure timely assistance is provided. Further, with technological advancement, the manufacturing cost has been reduced significantly. By using highly advanced automation, companies can reach economies of scale. Increasing profits and focusing more on R&D for better solutions are also priorities.


Environment concerns

Though wearable injectors are life-saving devices, they come at a cost to the environment. These devices are made of plastic bodies and are manufactured for one-time use purposes. Also, mishandling of devices and improper disposal of them can be hazardous. Since these devices need proper disposal and not all countries have a good disposal system, this not only affects other humans but also the ecosystem as plastic takes a long time to decompose.

Recent Developments:

  • United Therapeutics Corporation has introduced the Remunity subcutaneous pump for Remodulin, to help patients with pulmonary arterial hypertension (PAH).
  • BD (Becton, Dickinson and Company), has published results from a 52-subject human clinical trial with the BD Libertas Wearable Injector. This drug delivery system is in the final phases of development and is designed to deliver drugs such as biologics with viscosities up to 50 cP in 2-5 mL and 5-10 mL configurations.

COVID-19's Impact on the Wearable Injector Market

The coronavirus pandemic positively impacted the global wearable injector market. With the outbreak of the virus and restrictions, non-essential surgeries were avoided by both hospitals and clinics and patients in fear of the spread of the virus. Patients with cardiovascular disease, diabetes, and autoimmune disease, amongst others, were at high risk due to the coronavirus. Patients with high risk preferred to stay home in quarantine to avoid further risk. Furthermore, patients preferred to use self-administered devices like wearable injectors and Telehealthcare. This led to an increase in the demand for global wearable injectors.


By Type

  • On-Body Injectors
  • Off-Body Injectors

By Technology

  • Motor-driven
  • Expanding Battery
  • Spring-based
  • Rotary Pump

By Application

  • Oncology
  • Diabetes
  • cardiovascular Disease
  • Autoimmune Disease

By End-User

  • Hospitals and Clinics
  • Ambulatory Surgery Centres
  • Home Care Centres

By Geography

  • North America
  • USA
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Europe
  • Germany
  • France
  • UK
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Taiwan
  • Thailand
  • Indonesia
Frequently Asked Questions about the Wearable Injectors Market

What is the estimated value of the Wearable Injectors Market?

The Wearable Injectors Market was estimated to be valued at $4.64 billion in 2020.

What is the growth rate of the Wearable Injectors Market?

The growth rate of the Wearable Injectors Market is 20.6%, with an estimated value of $17.27 billion by 2027.

What is the forecasted size of the Wearable Injectors Market?

The Wearable Injectors Market is estimated to be worth $17.27 billion by 2027.

Who are the key companies in the Wearable Injectors Market?

Key companies in the Wearable Injectors Market include Medtronic, Amgen (Acquired by tenebio), Ypsomed, Insulet Corporation, West Pharmaceutical Services, Becton Dickinson And Company, Enable Injections, United Therapeutics Corporation, F. Hoffmann and La Roche AG.

Table of Contents

1. Introduction
1.1. Market Overview
1.2. Covid-19 Scenario
1.3. Market Definition
1.4. Market Segmentation
2. Research Methodology
2.1. Research Data
2.2. Assumptions
3. Executive Summary
3.1. Research Highlights
4. Market Dynamics
4.1. Market Drivers
4.2. Market Restraints
4.3. Porter's Five Forces Analysis
4.3.1. Bargaining Power of Suppliers
4.3.2. Bargaining Power of Buyers
4.3.3. Threat of New Entrants
4.3.4. Threat of Substitutes
4.3.5. Competitive Rivalry in the Function
4.4. Function Value Chain Analysis
5.1.  Introduction
5.2.  On body
5.3.  Off body
6.1.  Introduction
6.2.  Motor-driven
6.3.  Expanding Battery
6.4.  Spring-based
6.5.  Rotary Pump
6.6.  Others
7.1.  Introduction
7.2.  Hospitals and Clinics
7.3.  Ambulatory Surgery Centres
7.4.  Home Care Centres
8.1.  Introduction
8.2.  Oncology
8.3.  Diabetes
8.4.  cardiovascular Disease
8.5.  Autoimmune Disease
8.6. Others
9.1. Introduction
9.2.  North America
9.2.1.  USA
9.2.2.  Canada
9.2.3. Mexico
9.3.  South America
9.3.1.  Brazil
9.3.2. Argentina
9.3.3.  Others
9.4. Europe
9.4.1.  The United Kingdom
9.4.2. Germany
9.4.3. France
9.4.4. Others
9.5. Middle East and Africa
9.5.1. Saudi Arabia
9.5.2. UAE
9.5.3. Others
9.6.  Asia Pacific
9.6.1.  China
9.6.2. Japan
9.6.3.  India
9.6.4. South Korea
9.6.5. Taiwan
9.6.6. Thailand
9.6.7. Indonesia
9.6.8. Others
10.1.  Major Players and Strategy Analysis
10.2.  Emerging Players and Market Lucrative
10.3. Mergers, Acquisition, Agreements, and Collaborations
10.4.  Vendor Competitiveness Matrix
11.1.  Medtronic Plc.
11.2.  Amgen (Acquired by tenebio)
11.3.  Ypsomed
11.4.  Insulet Corporation
11.5.  West Pharmaceutical Services Inc.
11.6.  Becton, Dickinson, and Company
11.7.  Enable Injections
11.8.  United Therapeutics Corporation
11.9.  F. Hoffmann-La Roche AG
11.10.  Johnson & Johnson

Companies Mentioned

  • Medtronic
  • Amgen (Acquired by tenebio)
  • Ypsomed
  • Insulet Corporation
  • West Pharmaceutical Services
  • Becton Dickinson And Company
  • Enable Injections
  • United Therapeutics Corporation
  • F. Hoffmann-La Roche AG
  • Johnson & Johnson